Supplementary Figure S1 from Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

Kaplan-Meier curves for overall survival (A) and progressionfree survival (B) for all patients according tumor type (epithelioid and non-epithelioid subtypes)